Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 13, 2007

Celgene Plugs $20M into PTC Therapeutics

  • Celgene will make a $20 million equity investment in PTC Therapeutics. In return, Celgene will gain the right to enter an exclusive research deal related to two oncology targets for the development of small molecules with PTC’s GEMS (gene expression modulation by small molecules) technology.

    If Celgene exercises this option, PTC may receive funding for research efforts and milestone payments per target. Celgene will receive exclusive worldwide rights and pay PTC royalties on net sales of any products.

    The GEMS platform identifies small molecules that modulate post-transcriptional control mechanisms. These compounds target processes that act through the untranslated regions of mRNA.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »